Comparison of the effects of bupropion on nicotinic receptor-evoked [(3) H]dopamine release from rat striatal synaptosomes and slices

N Sidhpura, P Reffern, S Wonnacott

Research output: Contribution to journalArticle

  • 13 Citations

Abstract

Tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. The smoking cessation agent bupropion is an inhibitor of the dopamine transporter, but has also been shown to inhibit nicotinic acetylcholine receptors. To assess the relative impact of its actions at these two targets, we have examined the effects of bupropion on nicotine-evoked [H-3]dopamine release from rat striatal synaptosomes and slices, in the absence of any other transporter inhibitor. Bupropion (10 mu M) significantly decreased nicotine-evoked [H-3]dopamine release by similar to 50% in both preparations, consistent with the blockade of nicotinic receptors. In support of this interpretation, bupropion also selectively inhibited nicotine-evoked Ca2+ increases in SH-SY5Y cells. In striatal slices (but not in synaptosomes) the concentration-response profile for bupropion has an inverted 'u' shape, with a decrease in nicotine-evoked [H-3]dopamine release also observed in the presence of 0.1 mu M bupropion. This effect of 0.1 mu M bupropion (but not 10 mu M bupropion) was reversed by the dopamine D-2, receptor antagonist raclopride. We propose that modest blockade of the dopamine transporter by low concentrations of bupropion results in feedback inhibition via dopamine D-2 autoreceptors. This is overcome at higher concentrations of bupropion, before inhibition of nicotinic receptors occurs. Therefore bupropion's inhibition of the dopamine transporter and nicotinic receptors appears to be separated with respect to concentration.
LanguageEnglish
Pages102-109
Number of pages8
JournalEuropean Journal of Pharmacology
Volume567
Issue number1-2
DOIs
StatusPublished - Jul 2007

Fingerprint

Corpus Striatum
Bupropion
Synaptosomes
Nicotinic Receptors
Dopamine
Nicotine
Dopamine Plasma Membrane Transport Proteins
Raclopride
Autoreceptors
Aptitude
Dopamine Receptors
Smoking Cessation
Smoking

Cite this

Comparison of the effects of bupropion on nicotinic receptor-evoked [(3) H]dopamine release from rat striatal synaptosomes and slices. / Sidhpura, N; Reffern, P; Wonnacott, S.

In: European Journal of Pharmacology, Vol. 567, No. 1-2, 07.2007, p. 102-109.

Research output: Contribution to journalArticle

@article{5d4372eafd464fab84b98e69644d0916,
title = "Comparison of the effects of bupropion on nicotinic receptor-evoked [(3) H]dopamine release from rat striatal synaptosomes and slices",
abstract = "Tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. The smoking cessation agent bupropion is an inhibitor of the dopamine transporter, but has also been shown to inhibit nicotinic acetylcholine receptors. To assess the relative impact of its actions at these two targets, we have examined the effects of bupropion on nicotine-evoked [H-3]dopamine release from rat striatal synaptosomes and slices, in the absence of any other transporter inhibitor. Bupropion (10 mu M) significantly decreased nicotine-evoked [H-3]dopamine release by similar to 50{\%} in both preparations, consistent with the blockade of nicotinic receptors. In support of this interpretation, bupropion also selectively inhibited nicotine-evoked Ca2+ increases in SH-SY5Y cells. In striatal slices (but not in synaptosomes) the concentration-response profile for bupropion has an inverted 'u' shape, with a decrease in nicotine-evoked [H-3]dopamine release also observed in the presence of 0.1 mu M bupropion. This effect of 0.1 mu M bupropion (but not 10 mu M bupropion) was reversed by the dopamine D-2, receptor antagonist raclopride. We propose that modest blockade of the dopamine transporter by low concentrations of bupropion results in feedback inhibition via dopamine D-2 autoreceptors. This is overcome at higher concentrations of bupropion, before inhibition of nicotinic receptors occurs. Therefore bupropion's inhibition of the dopamine transporter and nicotinic receptors appears to be separated with respect to concentration.",
author = "N Sidhpura and P Reffern and S Wonnacott",
year = "2007",
month = "7",
doi = "10.1016/j.ejphar.2007.03.052",
language = "English",
volume = "567",
pages = "102--109",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Comparison of the effects of bupropion on nicotinic receptor-evoked [(3) H]dopamine release from rat striatal synaptosomes and slices

AU - Sidhpura,N

AU - Reffern,P

AU - Wonnacott,S

PY - 2007/7

Y1 - 2007/7

N2 - Tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. The smoking cessation agent bupropion is an inhibitor of the dopamine transporter, but has also been shown to inhibit nicotinic acetylcholine receptors. To assess the relative impact of its actions at these two targets, we have examined the effects of bupropion on nicotine-evoked [H-3]dopamine release from rat striatal synaptosomes and slices, in the absence of any other transporter inhibitor. Bupropion (10 mu M) significantly decreased nicotine-evoked [H-3]dopamine release by similar to 50% in both preparations, consistent with the blockade of nicotinic receptors. In support of this interpretation, bupropion also selectively inhibited nicotine-evoked Ca2+ increases in SH-SY5Y cells. In striatal slices (but not in synaptosomes) the concentration-response profile for bupropion has an inverted 'u' shape, with a decrease in nicotine-evoked [H-3]dopamine release also observed in the presence of 0.1 mu M bupropion. This effect of 0.1 mu M bupropion (but not 10 mu M bupropion) was reversed by the dopamine D-2, receptor antagonist raclopride. We propose that modest blockade of the dopamine transporter by low concentrations of bupropion results in feedback inhibition via dopamine D-2 autoreceptors. This is overcome at higher concentrations of bupropion, before inhibition of nicotinic receptors occurs. Therefore bupropion's inhibition of the dopamine transporter and nicotinic receptors appears to be separated with respect to concentration.

AB - Tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. The smoking cessation agent bupropion is an inhibitor of the dopamine transporter, but has also been shown to inhibit nicotinic acetylcholine receptors. To assess the relative impact of its actions at these two targets, we have examined the effects of bupropion on nicotine-evoked [H-3]dopamine release from rat striatal synaptosomes and slices, in the absence of any other transporter inhibitor. Bupropion (10 mu M) significantly decreased nicotine-evoked [H-3]dopamine release by similar to 50% in both preparations, consistent with the blockade of nicotinic receptors. In support of this interpretation, bupropion also selectively inhibited nicotine-evoked Ca2+ increases in SH-SY5Y cells. In striatal slices (but not in synaptosomes) the concentration-response profile for bupropion has an inverted 'u' shape, with a decrease in nicotine-evoked [H-3]dopamine release also observed in the presence of 0.1 mu M bupropion. This effect of 0.1 mu M bupropion (but not 10 mu M bupropion) was reversed by the dopamine D-2, receptor antagonist raclopride. We propose that modest blockade of the dopamine transporter by low concentrations of bupropion results in feedback inhibition via dopamine D-2 autoreceptors. This is overcome at higher concentrations of bupropion, before inhibition of nicotinic receptors occurs. Therefore bupropion's inhibition of the dopamine transporter and nicotinic receptors appears to be separated with respect to concentration.

UR - http://dx.doi.org/10.1016/j.ejphar.2007.03.052

U2 - 10.1016/j.ejphar.2007.03.052

DO - 10.1016/j.ejphar.2007.03.052

M3 - Article

VL - 567

SP - 102

EP - 109

JO - European Journal of Pharmacology

T2 - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -